What We Do
Creating ideal ocular therapeutics
The key to better ocular therapeutics is a highly potent affinity molecule that is also long-lasting and safely tolerated. Traditional antibodies suffer for this role due to its bulky size, low solubility, suboptimal stability, short half-life, and tendency to elicit an inflammatory response.
Our technology originates from more than 10 years of research at Stanford and UCSB and more than 20 peer-reviewed publications in top-tier journals. We discover novel affinity molecules that are immunologically inert, highly soluble, highly stable, and can leverage established sustained release technology to achieve significantly longer half-life.